Patients with acute leukemias relapsing within 1 year of an allogeneic BMT have a poor prognosis. We studied the use of melphalan 180 mg/m 2 followed by allogeneic peripheral blood stem cells (PBSC) as salvage treatment for patients relapsing after related (n = 7) or matched unrelated transplants (n = 3). Diagnoses were AML (n = 4), ALL (n = 3), biphenotypic acute leukemia (n = 2) and CML in blast crisis (n = 1). Eight patients were beyond first relapse and none were in remission. The median time from previous transplant to relapse was 146 days (range 66-206). The melphalan dose was 90 mg/m 2 intravenously on days −4 and −3 with PBSC infusion on day 0. GVHD prophylaxis consisted of cyclosporine and methylprednisolone. The median time to an absolute neutrophil count Ͼ0.5 × 10 9 /l and to a platelet count Ͼ20 × 10 9 /l was 11 and 13 days, respectively. All engrafting patients (n = 8) had 100% donor cells. Two patients died before day 30, but no other grade 3 or 4 toxicity occurred. Acute GVHD grades II-III occurred in two subjects, and chronic GVHD in four. Seven patients achieved CR, but relapsed at a median of 116 days (range 56-614). Leukemia was the cause of death in eight patients. Median survival was 149 days (range 6-614). This treatment produced responses in the majority of this poor prognosis group. However, durable remissions were not observed, and new treatments to consolidate the responses achieved in this setting are needed. This regimen could be considered for shortterm disease control to facilitate donor lymphocyte infusion-based immunotherapy or other measures to prevent disease recurrence. Bone Marrow Transplantation (2000) second myeloablative conditioning with allograft, 5 and enhancement of the graft-versus-leukemia effect by discontinuation of immunosuppressive therapy or addition of immunocompetent donor cells. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Other studies have involved stimulation of donor-derived immune responses or inhibition of the leukemic clone using cytokines such as interferon, G-CSF or interleukin-2. [19] [20] [21] [22] [23] Early relapses occurring during the first year post transplant carry an ominous prognosis with few patients responding to immune manipulation, chemotherapeutic maneuvers or second myeloablative therapies, which are associated with an extremely high risk of toxicity and treatment-related mortality.
chemotherapy for patients relapsing post allograft, and the existence of the graft-versus-leukemia effect has triggered interest in biologic approaches for remission re-induction. Strategies employed to date have included chemotherapy, 3, 4 second myeloablative conditioning with allograft, 5 and enhancement of the graft-versus-leukemia effect by discontinuation of immunosuppressive therapy or addition of immunocompetent donor cells. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Other studies have involved stimulation of donor-derived immune responses or inhibition of the leukemic clone using cytokines such as interferon, G-CSF or interleukin-2. [19] [20] [21] [22] [23] Early relapses occurring during the first year post transplant carry an ominous prognosis with few patients responding to immune manipulation, chemotherapeutic maneuvers or second myeloablative therapies, which are associated with an extremely high risk of toxicity and treatment-related mortality.
Immunological approaches such as interferon or donor lymphocyte infusion have been generally successful in chronic myelogenous leukemia (CML) relapsing in chronic phase, but not in acute leukemia or CML in transformed phases. The failure of immunological approaches in these diseases may be due in part to the proliferative rate of malignant cells and the long interval required for buffy coat infusions to exert an immune therapeutic effect. Cytoreduction with chemotherapy followed by reinfusion of both immunocompetent and hematopoietic progenitor cells could reinduce remissions in this setting. Cytoreduction with chemotherapy would allow donor-derived lymphocytes time to exert anti-leukemic activity, and donorderived progenitor cells would accelerate hematopoietic recovery. However, standard chemotherapeutic regimens have generally been ineffective in patients relapsing within the first year of allograft, 3, 4 and therefore novel strategies need to be pursued in this patient population. Melphalan is a bifunctional alkylator with a broad spectrum of activity in a variety of hematologic malignancies, which can be administered safely to heavily pretreated patients, with myelosuppression being its main toxicity even at doses of 140 to 200 mg/m 2 . [24] [25] [26] In the setting of early relapse post transplant, treatment with high-dose melphalan could provide adequate antileukemia therapy if supported by an allogeneic progenitor cell transplant to produce hematopoietic recovery and provide further donor effector cells to mediate a graft-versus-leukemia effect.
Here, we report the results of a pilot study for the treatment of acute leukemia relapsing after allogeneic transplan-Bone Marrow Transplantation tation with high-dose melphalan and donor PBSC. This study was conducted to assess re-induction of remission, engraftment, incidence of graft-versus-host disease and toxicity.
Patients and methods

Eligibility criteria
Patients were eligible for the study if they had acute leukemia or CML in accelerated phase or blast crisis that relapsed within a year after allogeneic blood or marrow transplantation. Patients were required to have adequate organ function and not have active acute or chronic graftversus-host disease (GVHD). Original BMT donors had to be willing to undergo G-CSF primed PBSC collection. The protocol was submitted to and approved by the Institutional Review Board of the MD Anderson Cancer Center, and all patients and donors provided written informed consent.
Patients' characteristics
From November 1993 to December 1996, 10 patients received high-dose melphalan followed by allogeneic PBSC from their original bone marrow donors as treatment for hematologic relapse of their leukemia within 1 year of their original transplant. Median age was 37 (range 7-45). Four patients had acute myelogenous leukemia (AML), three had acute lymphoblastic leukemia (ALL), two had biphenotypic acute leukemia, and one patient had CML in blast crisis. Median time from transplant to relapse was 146 days (range 66-206). The median time from initial diagnosis to transplant was 465 days (range 150-955). At the time of high-dose melphalan, five patients had failed withdrawal of immunosuppression with evidence of disease progression, at a median interval of 22 days (range 11-90). One patient with bi-phenotypic acute leukemia received methotrexate, vincristine, l-asparaginase and prednisone (MOAP) and achieved a short complete remission (CR), but disease recurred. None of the patients were in remission at the time of study entry. Patient and treatment characteristics are summarized in Tables 1 and 2 .
Treatment plan
The preparative regimen consisted of melphalan 90 mg/m 2 intravenously (i.v.) on days −4 and −3 with PBSC infusion on day 0. GVHD prophylaxis consisted of cyclosporine 3 mg/kg daily i.v. beginning on day −2, converted to a twice a day oral dose as tolerated. Doses were adjusted to maintain serum levels between 150 and 250 ng/ml. Methylprednisolone 0.5 mg/kg every 12 h was started on day +5 and converted to oral administration upon patient discharge from the hospital. On days +28 and +35 the dose was reduced to 0.3 and 0.2 mg/kg twice daily, respectively, and 50% reductions were done weekly thereafter. The tapering schedule was modified in the presence of GVHD as indicated. Treatment for grades II-IV acute GVHD consisted initially of methylprednisolone 0.5 mg/kg i.v. every 6 h. G-CSF 5 g/kg subcutaneously was started on day 0 and continued until an absolute neutrophil count greater than 2.5 × 10 9 /l was reached. Vancomycin 1 g i.v. daily, non-absorbable oral antibiotics, fluconazole 200 mg i.v. daily and acyclovir 5 mg/kg every 8 h were given for infection prophylaxis. Patients received intravenous immunoglobulin 500 mg/kg weekly to day +100 and monthly thereafter through the first year. Once engrafted, patients were given trimethoprimsulfamethoxazole orally or pentamidine by inhalation for Pneumocystis carinii prophylaxis.
Cytomegalovirus (CMV) prophylaxis was used when either the patient or the donor were seropositive, and consisted of ganciclovir 5 mg/kg i.v. every 12 h from admission to day −2 followed by acyclovir every 8 h from day −1 to engraftment, when ganciclovir was restarted at the same dose, 5 days per week, and continued to day 100.
Donor characteristics and PBSC collection
Seven donors were HLA-identical siblings and three were matched HLA-identical unrelated donors. Cells were collected from related donors at the MD Anderson Cancer Center. Donors received G-CSF (Amgen, Thousand Oaks, CA, USA) 10 g/kg/day in two subcutaneous injections daily for 4 days. PBSC were collected on days 4 and 5 during a large volume leukapheresis in a continuous flow blood cell separator (COBE Laboratories, Lakewood, CO, USA). The target number of mononuclear cells was Ͼ5 × 
Study endpoints, chimerism evaluation and statistical considerations
The main study endpoints were toxicity, achievement of complete remission, survival and disease-free survival. Neutrophil recovery was defined as the first of 2 consecutive days that the absolute neutrophil count (ANC) exceeded 0.5 × 10 9 /l and platelet recovery was defined as the first of 2 consecutive days that the platelet count exceeded 20 × 10 9 /l, with platelet transfusion independence. Chimerism was evaluated in the bone marrow using restriction fragment length polymorphism (RFLP) at the AY-29 or YNH24 loci, fluorescent in situ hybridization (FISH) for chromosomes X, Y using centromeric probes (Imagenetics, Framingham, MA, USA) (sex mismatched pairs) and the Philadelphia chromosome, or cytogenetics on unstimulated bone marrow cells using conventional methods for sex mismatched donor-recipient pairs. 27, 28 Bone marrow samples were obtained on engraftment and monthly thereafter, or in the case of evidence of relapse in the peripheral blood.
Complete remission was defined as Ͻ5% blasts in the bone marrow with a granulocyte count of Ͼ1.0 × 10 9 /l and platelets Ͼ100 × 10 9 /l with reconstitution of donor hematopoiesis as documented by cytogenetics or RFLP. Remission BMT = blood and marrow transplantation; HD = high-dose; AML = acute myelogenous leukemia; ALL = acute lymphocytic leukemia; CML = chronic myelogenous leukemia; MOAP = methotrexate, vincristine, l-asparaginase and prednisone; DC immune = discontinued immunosuppression; G-CSF = granulocyte colony-stimulating factor. Conditioning regimens: TBC = thiotepa, busulfan and cyclophosphamide; Cy/VP16/TBI = cyclophosphamide; vepeside and total body irradiation; Cy TBI = cyclophosphamide and total body irradiation.
a Received two previous BMT; regimen used on the second transplant. with partial hematologic recovery was defined as above, except for platelets Ͻ100 × 10 9 /l, and patients showing residual host hematopoiesis as determined by cytogenetics and RFLP were categorized as hematologic remission with mixed chimerism.
Regimen-related toxicity was graded according to the criteria of Bearman et al. 29 Adverse events related to culture-
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documented infections were not scored as treatmentrelated toxicity. The diagnosis of GVHD was based on the clinical picture with histologic confirmation. Acute and chronic GVHD grading followed standard criteria. 30, 31 Survival was measured from the day of transplant according to the methods of Kaplan and Meier. 32 
Results
Engraftment, chimerism and toxicity
The median number of mononuclear cells infused was 5.32 × 10 8 /kg (range, 1.12-10.9) recipient body weight and the median number of CD34 + cells was 5.63 × 10 6 /kg (range 1.16-8.6). Median time to an ANC Ͼ0.5 × 10 9 /l was 11 days (range 10-13) and to platelets Ͼ20 × 10 9 /l was 13 days (range 11-47) among the eight patients evaluable for engraftment. All engrafting patients had 100% donor cells according to either RFLP analysis or conventional cytogenetic techniques. Mixed chimerism was observed only on relapse.
Grade 2 mucositis occurred in three cases, and one patient developed grade 2 kidney and bladder toxicity. Two patients died before day 30 from multiorgan failure and infections. No other grade 3 or 4 toxicity was documented. Leukemia recurrence or progression caused the other eight deaths.
Acute and chronic GVHD
Grades II-IV acute GVHD occurred in two of eight evaluable patients (grade II and III), both responding to either steroids or steroids with anti-thymocyte globulin. Chronic GVHD was documented in four of eight evaluable patients; two of them had previously developed chronic GVHD after the first BMT ( Table 2 ). All patients responded to immunosuppressive therapy with steroids and/or cyclosporine.
Response and survival
Seven patients achieved a complete remission with four patients achieving platelet transfusion independence with a platelet count above 100 × 10 9 /l. Two patients had longer responses after the melphalan-based transplant than after their first BMT (Tables 2 and 3 ). All responding patients subsequently relapsed a median of 116 days post-transplant (range 54-614 days).
Early cyclosporine withdrawal was attempted in patients presenting with signs of impending relapse or recurrent leukemia. Three patients had cyclosporine discontinued prior to documentation of relapse, at post-transplant days 99, 99 and 106. Relapse occurred on days 116, 614 and 112, respectively. Two patients had cyclosporine withdrawn after relapse, on post-transplant days 60 and 130. Two patients developed acute GVHD and no attempt at cyclosporine withdrawal was made, one patient with resistant leukemia had cyclosporine withdrawn on day 40, and two patients were not evaluable. Two patients responded to immunomodulatory maneuvers (immunosuppression withdrawal in one patient and donor lymphocyte infusion in another) but died from infectious complications while in remission. The median survival for all patients was 149 days (range 6-614 days).
Discussion
Relapse remains the major cause of treatment failure after allogeneic hematopoietic transplantation. Time to relapse is the major prognostic factor; patients relapsing more than 1 year post transplant often tolerate second ablative transplants and approximately 20% achieve durable remissions. 33, 34 Those relapsing in less than 1 year have a grim prognosis. These patients are typically debilitated and cannot tolerate further intensive treatment, and their leukemia is highly resistant to therapy.
Immunomodulatory treatments have recently been evaluated. In the largest series of patients treated with donor lymphocyte infusions reported by Kolb et al, 17 response rates in the range of 80% were observed for patients with CML relapsing in chronic phase or with a cytogenetic relapse. Patients with AML had a 29% (five out of 17 evaluable patients) response rate with only complete response to chemotherapy predicting for survival after donor lymphocyte infusion. Our group of patients comprised cases unlikely to respond to immunotherapy with DLIs alone. In other studies, treatment of relapse after allogeneic transplant with chemotherapy resulted in complete responses in less than 10% of the cases so treated. 3 Thus, our patients would probably not have responded to conventional salvage chemotherapy. The addition of donor lymphocyte infusions to standard Ara-C-containing regimens for the treatment of relapsed myeloid leukemias after related bone marrow transplant seems to improve the results of donor lymphocyte infusions alone. Levine et al 35 reported 44 patients relapsing at a median of 214 days post transplant. Twentyfive patients (56%) achieved a complete response, with a Kaplan-Meier estimate of disease-free survival at 1 year of 20%.
Atkinson et al 33 were the first to report on the use of high-dose melphalan followed by a second allogeneic bone marrow transplant for patients who had relapsed after transplant. In their report of nine patients with acute leukemia or advanced CML who had relapsed between 4 and 33 months post transplant (median 14 months), seven patients received melphalan 220 mg/m 2 and two patients received melphalan 180 mg/m 2 . Four patients died within 4 months of the transplant from renal failure (n = 2), or infection. Three patients were alive in remission between 9 and 36 months post transplant.
Subsequently, Mehta et al 34 from the Royal Marsden Hospital, reported the outcome of leukemia relapsing after BMT. One of 23 post-allograft relapses treated with a second transplant was alive, with 14 deaths due to toxicity, as opposed to five out of 13 patients treated with immunotherapy and none of 78 patients receiving palliative or conventional salvage therapy. Of the 23 patients receiving a second allograft, 16 received single agent melphalan as the preparative regimen for the second allograft, of whom six had relapsed within a year of their initial allograft. All patients received bone marrow from the original donor as a stem cell source. Toxic deaths occurred in eight of the 16 patients, seven patients relapsed and one died in remission 3 years after the second allograft from complications of chronic GVHD.
In this study, we evaluated cytoreductive chemotherapy with second allogeneic PBSC transplant as a means of providing cytoreduction to control the relapsing acute leukemia and providing donor hematopoietic cells to restore hematopoiesis and potentially provide a graft-versusleukemia effect.
Allogeneic peripheral blood as a source of stem cells for relapsed patients may be superior to bone marrow. Retrospective analysis has demonstrated that recovery with peripheral blood progenitor cells is faster, regimen-related toxicity may be decreased and early survival improved, especially among high-risk patients. [36] [37] [38] The fact that the incidence of acute GVHD is not increased despite the infusion of one log more CD3
+ cells, suggests that filgrastim use alters the lymphocyte cytokine expression towards a type 2, 'non-inflammatory', CD4
+ T lymphocyte profile, with mobilization of type II dendritic cells. 37 Our study tends to support the concept that allogeneic peripheral blood stem cells may be the best source for rapid recovery and decreased regimen-related toxicity in patients undergoing second transplants. Unfortunately, in refractory patients with rapidly evolving leukemias, the increased incidence of chronic GVHD associated with peripheral blood progenitor cells may not be sufficient to allow for long-term disease control. 39 All seven evaluable patients were complete chimeras by RFLP post transplant. Pretransplant all but three patients had predominantly recipient DNA or were mixed chimeras pre-BMT, including the three patients who received unrelated PBSC, supporting that in this setting melphalan by itself is immunosuppressive enough to allow for engraftment of unrelated donor cells.
The high response rate achieved with melphalan in this poor risk group of patients relapsing within 1 year of blood and marrow transplant did not translate into prolonged remissions. Several strategies are being investigated that could prolong remissions and survival in this context. Purine analogs such as fludarabine inhibit ongoing DNA repair; 40 the addition of drugs that induce DNA damage and subsequently repair, may potentiate the anti-leukemia effect of each drug. The combination of fludarabine and melphalan appears to be both immunosuppressive and active against several hematological malignancies; 41 this combination may provide a better regimen for the treatment of leukemia relapse post allogeneic transplant, allowing enough cytoreduction and time for allogeneic cells to exert the graft-versus-leukemia effect. In the context of low burden disease, the use of prophylactic donor lymphocyte infusions with rapid tapering of GVHD prophylaxis may also magnify the cytoreduction achieved with the preparative regimen, and induce complete chimerism. 42, 43 This approach of a reduced toxicity preparative regimen with allogeneic stem cell transplantation provides a potential platform to assess novel immunotherapeutic strategies, such as engineered T cell populations designed to mediate antileukemia reactivity without GVHD. 44 In conclusion, melphalan 180 mg/m 2 followed by allogeneic PBSC transplant produces responses and transient remissions in the majority of heavily treated patients relapsing within a year after an allogeneic BMT. However, this regimen did not produce durable remissions, and new strategies designed to prevent relapse are urgently needed.
